Deadline: 9th July 2012 for expression of interest
The aim of IMI is to propose a coordinated approach to overcome identified research bottlenecks in the drug development process, in order to accelerate the development of safe and more effective medicines for patients, by fostering collaboration between all stakeholders such as industry, public authorities (including regulators), organisations of patients, academia and clinical centres, and enhancing Europe’s competitiveness.
The IMI 6th Call 2012 consists of two topics:
1 : Innovative Trial Design and Clinical drug development
IMI encourages small and medium-sized enterprises (SMEs), patients’organisations, regulatory authorities, academic teams, industry, hospitals and other organisations to form consortia and apply for participation in the new IMI projects.
- Take part in patient-centric biomedical / pharmaceutical research
- Join unique consortia involving top teams from industry, academia, SMEs, regulators, and others
- Obtain research funding
- Gain access to the databases, knowledge and infrastructures of consortium partners
- Boost the visibility and status of your organisation in Europe and globally and gain access to new markets